As Initial Healthcare Reform Period Closes, China Allows More High-Price Drugs In Community Clinics
This article was originally published in PharmAsia News
You may also be interested in...
China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits
SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses
SHANGHAI - While many investors are looking forward to a rebound in the second half of 2011 following a disappointing first half, analysts from Morgan Stanley poured cold water on investor hopes in Hong Kong by downgrading pharma and distribution sectors in a July 7 research note
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.